Novel Immunotherapy for Brain Cancer
脑癌的新型免疫疗法
基本信息
- 批准号:8833722
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-25 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdultAnaplastic astrocytomaAnimal ModelAntibodiesAntibody TherapyAntigensBindingBiological ProductsBiologyBrainBreastCancer PatientCellsCervicalClinicalClinical assessmentsComplexDiseaseDisease remissionEpitopesExcisionFailureFucoseFutureGlioblastomaGliomaGrowthHealthHistologyHumanImmuneImmune systemImmunotherapyIn complete remissionIndiumJapanLicensingLungMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of cervix uteriMediator of activation proteinMolecular GeneticsMonoclonal AntibodiesMusNatureNewly DiagnosedNicotianaNormal CellNormal tissue morphologyOperative Surgical ProceduresOvarianPancreasPatientsPhasePlantsPolysaccharidesPrimary Brain NeoplasmsRadiation therapyRecording of previous eventsRecurrenceResearchSpecificityStomachStructureSurfaceSurvival RateSystemTherapeuticTimeTranslatingVariantVimentinVirusXenograft ModelXyloseantibody-dependent cell cytotoxicitybasebevacizumabbrain cellbrain tissuecancer cellchemotherapyimprovedin vitro activitynoveloutcome forecastpartial responsepublic health relevanceresearch clinical testingrespiratorysuccesstherapeutic targettumor
项目摘要
DESCRIPTION (provided by applicant): Glioblastoma is the most common primary brain tumor in adults. While many patients achieve disease remission following treatment with surgical resection, radiation therapy and chemotherapy, this remission is brief and invariably followed by tumor recurrence and progression. The failure to offer durable therapies to patients with glioblastoma reflects the complex nature of this cancer. Targeted therapies involving monoclonal antibodies (mAbs) have had remarkable success in various diseases including cancer. Unfortunately, the current targeted therapy for glioblastoma, bevacizumab, has had disappointing clinical results. There is a clear need for alternative targeted therapies for glioblastoma that can potentially improve overall survival of newly diagnosed patients. This proposal is intended to further develop an antibody against a cancer-specific antigen that has shown promising clinical results in humans. We will be exploring the possibility that the non-fucosylated mAb variant will have enhanced ADCC activity in vitro that will ultimately translate into enhanced therapeutic benefit in animal models. This research will be the first time that a non-fucosylated mAb will be evaluated in the context of brain malignancy.
描述(由申请人提供):胶质母细胞瘤是成人中最常见的原发性脑肿瘤。虽然许多患者在手术切除、放疗和化疗治疗后达到疾病缓解,但这种缓解是短暂的,并且总是伴随着肿瘤复发和进展。未能为胶质母细胞瘤患者提供持久的治疗反映了这种癌症的复杂性。涉及单克隆抗体(mAb)的靶向治疗在包括癌症在内的各种疾病中取得了显著的成功。不幸的是,目前针对胶质母细胞瘤的靶向治疗贝伐单抗的临床结果令人失望。对于胶质母细胞瘤的替代靶向疗法存在明确的需求,其可以潜在地改善新诊断患者的总生存期。该提案旨在进一步开发针对癌症特异性抗原的抗体,该抗体已在人类中显示出有希望的临床结果。我们将探索非岩藻糖基化mAb变体在体外具有增强的ADCC活性的可能性,这将最终转化为动物模型中增强的治疗益处。这项研究将是首次在脑恶性肿瘤的背景下评价非岩藻糖基化mAb。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew C Hiatt其他文献
Andrew C Hiatt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew C Hiatt', 18)}}的其他基金
Monoclonal Antibodies for Alzheimer's Immunotherapy
用于阿尔茨海默病免疫治疗的单克隆抗体
- 批准号:
7405560 - 财政年份:2005
- 资助金额:
$ 22.5万 - 项目类别:
Monoclonal Antibodies for Alzheimer's Immunotherapy
用于阿尔茨海默病免疫治疗的单克隆抗体
- 批准号:
7617622 - 财政年份:2005
- 资助金额:
$ 22.5万 - 项目类别:
相似海外基金
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
由生物标志物驱动的 DB107(一种逆转录病毒复制载体)与 5-FC 联合治疗复发性胶质母细胞瘤或间变性星形细胞瘤患者的 2 期研究
- 批准号:
10722246 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
M032(一种表达 IL-12 的基因工程 HSV-1)在复发/进行性多形性胶质母细胞瘤、间变性星形细胞瘤或胶质肉瘤患者中的 1 期研究。
- 批准号:
9455636 - 财政年份:2017
- 资助金额:
$ 22.5万 - 项目类别:
PHARMACOKINETICS OF SODIUM BOROCAPTATE IN ANAPLASTIC ASTROCYTOMA
硼己酸钠在间变性星形细胞瘤中的药代动力学
- 批准号:
6418826 - 财政年份:2000
- 资助金额:
$ 22.5万 - 项目类别:
PHARMACOKINETICS OF SODIUM BOROCAPTATE IN ANAPLASTIC ASTROCYTOMA
硼己酸钠在间变性星形细胞瘤中的药代动力学
- 批准号:
6112914 - 财政年份:1998
- 资助金额:
$ 22.5万 - 项目类别:
PHASE II STUDY OF TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺治疗初次复发的间变性星形细胞瘤的 II 期研究
- 批准号:
6275974 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别:
TEMOZOLOMIDE IN TREATMENT OF ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺治疗初次复发的间变性星形细胞瘤
- 批准号:
6244474 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别:
TEMOZOLOMIDE (SCH52365) IN PATIENTS W/ ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺 (SCH52365) 用于首次复发的间变性星形细胞瘤患者
- 批准号:
6244603 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别:
PHASE II STUDY OF TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺治疗初次复发的间变性星形细胞瘤的 II 期研究
- 批准号:
6245859 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别:
TEMOZOLOMIDE IN THE TREATMENT OF ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺治疗初次复发的间变性星形细胞瘤
- 批准号:
6246438 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别:
PHASE I STUDY OF TEMOZOLOMIDE IN TREATMENT OF ANAPLASTIC ASTROCYTOMA
替莫唑胺治疗间变性星形细胞瘤的 I 期研究
- 批准号:
6246373 - 财政年份:1997
- 资助金额:
$ 22.5万 - 项目类别: